Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs.

Syntis Bio是一家临床阶段的生物制药公司，致力于革新肥胖症、糖尿病和罕见病的口服疗法，该公司今天宣布完成了3300万美元超额认购的A轮融资。Cerberus Ventures领投了本轮，新投资者Mansueto Investments、Woori Venture Partners和Apollo Labs也参与其中。

Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures also participated. Syntis has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supporting the advancement of its SYNT™ (SYNthetic Tissue-lining) platform..

创始投资者BOLD Capital Partners、W. R. Berkley Corporation、Safar Partners、Portal Innovations、Colorcon Ventures和Cerity Partners Ventures也参与其中。Syntis还通过国家糖尿病、消化和肾脏疾病研究所（NIDDK）的两项快速通道小企业创新研究（SBIR）奖项，从美国国立卫生研究院（NIH）获得了高达500万美元的非稀释性资金，用于支持其SYNT™（合成组织衬里）平台的发展。

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption.

Syntis Bio是一家临床阶段的生物制药公司，致力于开发口服疗法，利用小肠的独特生物学特性，为从罕见遗传病到全球最普遍疾病在内的整个医疗领域提供更易获取、更有效和更可持续的解决方案。Syntis正在快速推进一系列针对小肠活动的口服疗法，小肠是人体代谢控制、消化和药物吸收的核心。

Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders..

除了其主要的肥胖症项目SYNT-101外，该公司还在推进一系列针对罕见代谢疾病和肠道相关疾病的疗法组合。